Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia

Hsien-yang Lee1, Junko Nakayama, Ying Xu

  • 1Department of Neurology, UCSF, San Francisco, California, USA.

Insights

Paroxysmal nonkinesigenic dyskinesia (PNKD) is a movement disorder linked to PNKD gene mutations. Research shows the PNKD protein modulates neurotransmitter release in the brain, with mouse models mimicking human symptoms.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Paroxysmal nonkinesigenic dyskinesia (PNKD) is an autosomal dominant episodic movement disorder.
  • PNKD episodes are triggered by alcohol, coffee, and stress, lasting 1-4 hours.
  • Mutations in the PNKD gene on chromosome 2q33-q35 cause PNKD.

Purpose of the Study:

  • To generate antibodies for the PNKD protein.
  • To investigate the expression and function of the PNKD protein in the brain.
  • To develop and characterize a mouse model for PNKD.

Main Methods:

  • Generation of PNKD-specific antibodies.
  • Immunohistochemical analysis of PNKD protein expression in mouse brain.
  • Creation and behavioral/biochemical analysis of transgenic PNKD mice.

Main Results:

  • PNKD protein is widely expressed in mouse neurons, with one isoform being membrane-associated.
  • Transgenic mice with PNKD mutations exhibit human-like PNKD phenotypes.
  • Alcohol and caffeine induced neuronal activity in the basal ganglia and altered dopamine levels in PNKD mice.

Conclusions:

  • The PNKD protein modulates striatal neurotransmitter release.
  • PNKD protein dysfunction contributes to movement disorder symptoms.
  • PNKD mouse models are valuable for studying the disorder and potential treatments.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.